Monte Rosa Therapeutics Inc. (GLUE) is a clinical-stage biotechnology company advancing a portfolio of molecular glue degraders (MGDs), a novel class of small molecules designed to harness the body's natural protein degradation pathways.
With three programs in clinical development, strategic collaborations with Novartis and Roche, and a proprietary discovery engine known as QuEEN (Quantitative and Engineered Elimination of Neosubstrates), the company is attempting to redefine therapeutic possibilities across oncology, immunology, and inflammation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com